FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Positive Results Released for Novartis’ BAF312 in Secondary Progressive MS Patients

























Image Source: NEWSLOCKER

By Editorial Team

Pharmaceutical giant Novartis released promising news ahead of the official release of their results from the largest controlled study surrounding individuals with secondary progressive multiple sclerosis (SPMS).1  SPMS generally supersedes relapse-remitting multiple sclerosis (RRMS) in the progression of MS.  At this stage, individuals experience a degradation of neurological function, and previously, there have been few treatment options for this population.

Although the results of the 1,651 patient Phase III EXPAND trial are set to be discussed in detail in London next month at the European Committee for Treatment and Research in Multiple Sclerosis (ETRIMS), Novartis has just revealed that the randomly controlled trial succeeded in meeting its primary endpoint. This goal was for individuals taking 2mg of once-daily BAF312 (siponimod) to display a reduced risk of three-month confirmed disability progression when compared to their counterparts given a placebo.  The study had a 2:1 ratio of treatment versus placebo, and the disability progression was measured using the expanded disability status scale (EDSS).

The new BAF312 medication is a modulator for certain S1P receptor cells in the central nervous system.  These receptor cells play a role in the loss of neurological function in individuals with SPMS.  Controlling these receptor cells could be the key to halting the loss of function in SPMS.  With few treatment options for individuals with SPMS, the need for something that shows promise is key.

“SPMS is a particularly disabling form of MS, and there is a need for effective treatment options to help delay disability progression in those living with the condition.  The positive EXPAND data are encouraging for a disease with such a high unmet need.”

-Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis

Whether or not any of the secondary endpoints of the 31-country-spanning study were fulfilled—which include a decrease in the time to 6-month confirmed disability progression versus placebo, T2 lesion volume, annualized relapse rate, time to confirmed worsening of at least 20% from baseline in the timed 25-foot walk test, and the overall tolerability and safety of the new treatment—has not yet been disclosed.  These results are among those expected to be discussed in London next month as well.

Novartis currently has medications on the market for RRMS, including Gilenya (fingolimod) and Extavia (interferon beta-1b for subcutaneous injection), as well as the current development and testing of a monoclonal antibody in-licensed from GlaxoSmithKline called ofatumumab (OMB157).  However, BAF312 will be the first geared towards individuals with SPMS.  According to these preliminary results, the drug seems to be a promising and much needed treatment geared towards individuals with SPMS, that Novartis is aiming to get to regulators to implement for treatment in 2019.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSIS.NET
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News